(redirected from autologous transplant)
Also found in: Dictionary, Medical, Encyclopedia.
Related to autologous transplant: allogeneic transplant, syngeneic transplant
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Synonyms for autograft

tissue that is taken from one site and grafted to another site on the same person


Related Words

References in periodicals archive ?
Today, "some centers perform autologous transplant outpatient, but our patients are generally discharged the day after transplant," Parran says, "while those undergoing unrelated allogeneic transplants generally stay around a month.
Also, no researchers had adequately compared protracted consolidation/maintenance chemotherapy--the mainstay of treatment for acute lymphocytic leukemia (ALL)--with autologous transplant to determine efficacy.
Holding back tears she said: "The autologous transplant will only prolong Wesley's life a little more than six months.
Adam has not been in remission once in the nine years he has had the disease and has undergone treatment from numerous courses of chemotherapy to what is known as an autologous transplant, where your bone marrow is taken out of your body and cleaned before being put back in again.
Exactly how can scientists answer the question, "What are the odds that a child will require an autologous transplant in his or her life time?
Patients must remain in isolation for six weeks while the autologous transplant takes hold.
SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it has initiated a pivotal trial of Captisol-enabled([R]), propylene glycol-free (PG-free) high-dose melphalan as a conditioning treatment prior to autologous transplant for patients with multiple myeloma.
About 60% of patients with multiple myeloma achieved complete remission when a conventional autologous transplant was combined with a nonmyeloablative allogenic transplant, Dr.
The issue of high dose chemotherapy and autologous transplant is a good example.
Ligand's Captisol-enabled melphalan program, which has been granted Orphan Drug status by the FDA as a conditioning treatment for use in autologous transplant for patients with multiple myeloma, is a new IV formulation of melphalan (currently sold as Alkeran([R]) for Injection) that has the potential to offer multiple advantages for clinicians and patients in the multiple myeloma transplant setting.
Mozobil, in combination with G-CSF, is designed to release hematopoietic stem cells from the bone marrow into the bloodstream where they can be collected, making it more likely for patients with certain types of cancers to proceed to autologous transplant.
Elderly patients who cannot receive an autologous transplant receive combinations of chemotherapies in first line treatment (melphalan, cyclosphosphamide, corticoids) associated with Thalidomide[R] or Velcade[R].
Most of the multiple myeloma (ML) patients age 70 or older are offered less effective non-transplant treatments that in the long run may be more toxic and expensive than a single autologous transplant.
Patients in the company's pivotal Hodgkin lymphoma trial had all relapsed following autologous transplant, but none had received an allogeneic transplant.
Full browser ?